CIC (Cambridge Innovation Center)’s Post

📣 Our focus is on OATD-01 and its breakthrough therapy potential, and progress of OATD-02 trial in patients with solid tumors, which led to reduction of programs in the discovery from five to three.  Key areas for further development and value building for #Molecure are: #OATD01 as a potential breakthrough therapy for the treatment of sarcoidosis and MASH, and #OATD02 in trials in patients with solid tumors. Development of projects in the discovery phase powered by machine learning and generative artificial intelligence (GenAI) methods includes a small-molecule drug discovery platform that modulates #mRNA translational function and the USP7 program. ➡️ For more information click here: https://lnkd.in/ekeFW-QY

🎗️We've just unveiled an exclusive collaboration with Dr. Artem Cherkasov and have integrated a proprietary Deep Docking AI Platform for DNA-damage response targets into our business model. With this proprietary AI platform, we're revolutionizing the discovery and development of targeted cancer drugs. 🧬💊 Our team can now rapidly evaluate billions of molecular structures, focusing on DNA-damage response-related vulnerabilities prevalent in various cancer types. This innovative approach enables us to expedite the drug discovery process.💡 From preclinical research to human clinical trials and potential partnerships, we're accelerating the journey to groundbreaking therapies. Our commitment to advancing precision medicine and delivering hope to millions of patients remains steadfast. 💪 With the support of Dr. Artem Cherkasov and the Deep Docking AI Platform, Rakovina is poised to make significant strides in the fight against cancer. 🌟 Join us as we embark on this transformative journey! Together, we're reshaping the future of cancer treatment. 🌌 #RakovinaTherapeutics #PrecisionMedicine #AIinHealthcare #CancerResearch 🎉 https://lnkd.in/gxS59_6A

T-1 day until DDIF 2024 GBX EVENTS kicks off! Excited to dive into groundbreaking presentations from industry leaders on innovations in digital transformation, GenAI, AI-driven drug discovery, and more. Key topics: - GenAI's role in healthcare and pharma - Transforming cancer and age-related treatments with AI and cell therapy - Patient-first drug discovery - The impact of quantum computing Looking forward to the fireside chats and hearing insights from CxOs about their journey and vision for the future. Exciting times for healthcare ahead!

ConcertAI has announced 3 new products this week at the American Society Of Cancer Oncology's annual meeting! This comes alongside ConcertAI partnering with NVIDIA to help create and develop new clinical simulations. Concert AI has said the partnership will be focused on collaborative R&D. It will allow for large-scale clinical simulations that have billions of data points per patient. These will be used to inform trial design, decision-making models, large language models for precision oncology, and models that retrieve clinical information in real time. Let me know what you think about the advancements to Oncology this could make. Credit to Fierce Pharma for this up to date article. Link Below: https://lnkd.in/eSzH_iaz #CRO #AI #Artificialintelligence #Lifescience #contractresearch

AI has been a game-changer in the field of cancer research and treatment. I'm thrilled to share that next week I’ll be engaging in a Fireside chat with Laura Chang, the editorial director at STAT, to discuss "AI and the Future of Cancer Care" at the upcoming STAT Breakthrough Summit East. The summit will kick off with an introduction by Matthew Herper. Join me in person or online to learn more about how AI is revolutionizing cancer care and engage in thought-provoking discussions on the future of healthcare. #cancerresearch #AI #STATsummit

🔬Elevate Your Lab's IHC Capabilities with ViewsML’s Virtual IHC🔬 Imagine a world where your IHC needs are met with unmatched versatility and efficiency. With ViewsML's Virtual IHC, that world is here. Our platform adapts seamlessly to any species, tissue type, or biomarker, providing precise, reproducible results without the hassle of traditional lab work. Say goodbye to labor-intensive, costly processes and hello to a streamlined workflow. Consistent, reliable, and powerful—this is the future of lab research. Don't let traditional IHC hold you back. Embrace the future with ViewsML💎 Visit our website to learn more and book a demo call today. #ResearchInnovation #Immunohistochemistry #VirtualIHC #Biomarkers #LabEfficiency #IHC #Oncology #Cancerresearch #Drugdiscovery #Clinicaltrials #Preclinicalresearch

The fourth edition is out! In this edition: ⚫ Trending topics: Wearable breast pump and adaptogen drinks ⚪ Traction: Day One Biopharmaceuticals’s OJEMDA receives FDA approval to treat childhood brain tumor, PulseSight Therapeutics just launched and is looking for Series A investors and more ⚫ Research Topics: Researchers create artificial cells that act like living ones, AI beats doctors in accurately assessing eye problems and more ⚪ Deep Dive: Freenome ⚫ Recent Fundraising: Cell BioEngines, Inc, Flyte, Red Arrow Therapeutics, Siren Biotechnology and more ⚪ Early Days: Headspace ⚫ Successful Exits: Kühne Holding B.V. acquired Aenova Group, GEDiCube/ RenovaroCube acquires Cyclomics and more ⚪ Investor Portfolio: Engine Ventures Augmented Sapiens, written with investors in mind, dive into the intersection of health, performance and longevity, exploring innovation solutions that are shaping the future of wellness. The newsletter shares recent tractions, trending topics, recent funding and exits from biotech, health, and life science companies.

We’re at #BIOEurope2024! Our Chief Business Officer, Scott Cuthill, and Chief Technology Officer, Jacob Hurst, are there connecting with fellow biotech innovators and thought leaders in the industry. Our proprietary platform, EMLy™, integrates machine learning with human expertise to predict and engineer therapeutic T Cell Receptors (TCRs) and  antibodies. We are currently harnessing EMLy’s advanced LLM capabilities to analyse the immune repertoires of long-term cancer survivors, aiming to identify novel targets that could lead to breakthrough treatments. If you're attending BIO-Europe, be sure to catch Scott or Jacob to find out more about EMLy. Can’t make it to the conference? Reach out to us at info@etcembly.com to start a conversation! #Biotech #Techbio #immunotherapies #CancerResearch #antibodies #TCRs #AI #LLMs

We are very excited that #AACR24 is in full swing! Please stop by booth #4351 and speak with the EMIT Imaging team to discuss how 3D, Cryo-Fluorescence Tomography is helping preclinical oncology researchers discover more with enhanced visualization of drug PK/PD in whole animals. #fluorescenceimaging #preclinicalresearch #preclinicalimaging #CFT

Biopharma companies generate a lot of proprietary data. But as the Benchling State of Tech in Biopharma report indicates, large and small Biopharma companies struggle to successfully leverage ML solutions in their discovery pipelines. At Ensemble, we’re meeting this industry need with scalable technology that automates data mapping and integration. Our “Dark Matter” solution plugs into existing data pipelines to uncover meaningful patterns and insights across complex data sets. The result? A machine learning stack that measurably accelerates decision-making and innovation. The proof? Consider our case study focused on the open-source Kinase Cancer Inhibitor dataset. Dark Matter demonstrably boosted the performance of linear and non-linear classification algorithms in identifying top-performing inhibitors. (Link: https://buff.ly/3ZKvi3a ) Better data = Better predictions. Get in touch for a demo or to learn more. https://buff.ly/3BbNKbp #BioPharma #AIReady #DrugDiscovery #Innovation#DataScience